Enzymatic defluorination of a terminally monofluorinated pentyl moiety: oxidative or hydrolytic mechanism?
Autor: | Haschimi B; Forensic Toxicology, Institute of Forensic Medicine, Germany., Willecke F; Preclinical Pharmacokinetics and Metabolism, Idorsia Pharmaceuticals Ltd., Switzerland., Mundinger S; Insitute of Organic Chemistry, Albert-Ludwigs-University Freiburg, Germany., Hüttel W; Insitute of Organic Chemistry, Albert-Ludwigs-University Freiburg, Germany., Jessen H; University of Freiburg, Germany., Müller M; Insitute of Pharmaceutical Sciences, Albert-Ludwigs-University Freiburg, Germany., Auwärter V; University of Freiberg, Germany volker.auwaerter@uniklinik-freiburg.de. |
---|---|
Jazyk: | angličtina |
Zdroj: | Drug metabolism and disposition: the biological fate of chemicals [Drug Metab Dispos] 2024 Feb 26. Date of Electronic Publication: 2024 Feb 26. |
DOI: | 10.1124/dmd.123.001501 |
Abstrakt: | Fluorination of organic compounds plays an important role in the chemical and pharmaceutical industry and is often applied in order to improve physicochemical parameters or modify pharmacological properties. While oxidative and reductive defluorination have been shown to be responsible for the metabolic degradation of organofluorine compounds, the involvement of hydrolytic mechanisms catalyzed by human enzymes has not been reported so far. Here, we investigated the enzymatic defluorination of terminally monofluorinated aliphates with [1-(5-fluoropentyl)-1 H -indol-3-yl]-1-naphthalenyl-methanone (AM-2201) as a model substance. We performed in vitro biotransformation using pooled human liver microsomes (pHLM) and human recombinant cytochrome P450 (CYP) assays. In order to elucidate the underlying mechanisms, modified incubation conditions were applied including the use of deuterium labeled AM-2201 ( d (Copyright © 2024 American Society for Pharmacology and Experimental Therapeutics.) |
Databáze: | MEDLINE |
Externí odkaz: |